COPN Stock Overview
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 69.50 |
52 Week High | CHF 81.50 |
52 Week Low | CHF 68.50 |
Beta | 1.25 |
11 Month Change | -12.58% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -14.20% |
Recent News & Updates
Recent updates
Shareholder Returns
COPN | AT Pharmaceuticals | AT Market | |
---|---|---|---|
7D | -1.4% | -3.3% | 0.2% |
1Y | n/a | 6.3% | 2.2% |
Return vs Industry: Insufficient data to determine how COPN performed against the Austrian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how COPN performed against the Austrian Market.
Price Volatility
COPN volatility | |
---|---|
COPN Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 3.4% |
10% most volatile stocks in AT Market | 6.1% |
10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine COPN's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 339 | Giovanni Di Napoli | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
COPN fundamental statistics | |
---|---|
Market cap | €1.11b |
Earnings (TTM) | €69.57m |
Revenue (TTM) | €185.36m |
16.0x
P/E Ratio6.0x
P/S RatioIs COPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COPN income statement (TTM) | |
---|---|
Revenue | €185.36m |
Cost of Revenue | €43.62m |
Gross Profit | €141.74m |
Other Expenses | €72.16m |
Earnings | €69.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 4.34 |
Gross Margin | 76.47% |
Net Profit Margin | 37.53% |
Debt/Equity Ratio | 0.1% |
How did COPN perform over the long term?
See historical performance and comparison